Anika Therapeutics (ANIK) Total Current Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Current Liabilities data on file, last reported at $21.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $21.0 million, up 17.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.0 million (up 17.12% YoY), and the FY2025 annual result was $21.9 million, down 6.0% from the prior year.
• Total Current Liabilities fell to $21.0 million in Q1 2026 per ANIK's latest filing, from $21.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.1 million in Q4 2023 and troughed at $16.1 million in Q2 2025.
• A 5-year average of $24.8 million and a median of $26.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities tumbled 42.54% in 2022, then climbed 17.12% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $27.9 million in 2022, then increased by 11.27% to $31.1 million in 2023, then slipped by 24.96% to $23.3 million in 2024, then declined by 6.0% to $21.9 million in 2025, then declined by 4.3% to $21.0 million in 2026.
• Business Quant data shows ANIK's Total Current Liabilities at $21.0 million in Q1 2026, $21.9 million in Q4 2025, and $19.1 million in Q3 2025.